Patients with benign and malignant gynecological diseases (e.g., endometriosis, uterine fibroids, premalignant and malignant lesions of the vulva, vagina, uterus, adnexa, and breast)
Conditions
Interventions
Group 1: During essential medical procedures, tissue samples are obtained from patients. Tissue not required for diagnostic purposes is processed into 'precision tissue slices' or organoids to investi
Sponsors
Universitätsmedizin Mainz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of a malignant or benign gynecological disease Surgical intervention performed at the University Medical Center Mainz Histopathological evaluation conducted at the Institute of Pathology, University
Exclusion criteria
Exclusion criteria: -age under 18 years -no informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigation of the pathogenesis and development of novel therapeutic options for benign and malignant gynecological diseases. Goals of the study: -Identification of pathomechanisms underlying disease and tumor development in benign and malignant gynecological disorders -Efficacy testing of established therapeutics, particularly in the context of novel combination therapies -Prediction of the effectiveness of new therapeutic agents -Identification of the activation and role of immune cells within the tumor microenvironment in response to drug therapies -Interaction between diseased tissue and immune cells under the influence of pharmacological treatments | — |
Secondary
| Measure | Time frame |
|---|---|
| see Primary outcome | — |
Countries
Germany
Contacts
Public ContactRoxana Schwab
Universitätsmedizin Mainz
Outcome results
None listed